Compare OTLK & BCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OTLK | BCG |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 39.8M |
| IPO Year | 2016 | N/A |
| Metric | OTLK | BCG |
|---|---|---|
| Price | $0.51 | $2.51 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $3.83 | N/A |
| AVG Volume (30 Days) | ★ 12.7M | 29.7K |
| Earning Date | 02-13-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | $1,413,535.00 | ★ $178,203,000.00 |
| Revenue This Year | $1,578.49 | N/A |
| Revenue Next Year | $153.58 | N/A |
| P/E Ratio | ★ N/A | $69.41 |
| Revenue Growth | N/A | ★ 10.19 |
| 52 Week Low | $0.50 | $1.36 |
| 52 Week High | $3.39 | $5.81 |
| Indicator | OTLK | BCG |
|---|---|---|
| Relative Strength Index (RSI) | 25.51 | 51.56 |
| Support Level | $0.51 | $2.25 |
| Resistance Level | $0.54 | $2.68 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 16.19 | 37.59 |
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.